The new Liverpool Clinical Research Facility (CRF) unit has opened at the new Royal Liverpool University Hospital thanks to £5.3m ($6.4m) funding from the National Institute for Health Research (NIHR). The CRF will explore new treatments and vaccines for a range of diseases prevalent in Liverpool’s communities. This… Read More
A Phase I safety and pharmacodynamic activity trial shows IMC-M113V, the first soluble T cell receptor (TCR) therapy for people living with HIV, is well tolerated. Immunocore presented the findings at the Conference on Retroviruses and Opportunistic Infection (CROI). The bispecific soluble TCR therapy built… Read More
Biopharmaceutical company Basking Biosciences has revealed positive Phase I study results for its reversible thrombolytic therapeutic for ischaemic stroke. The company’s novel von Willebrand Factor (vWF)-targeting thrombolytic agent, BB-031 demonstrated safety and tolerability following a single intravenous dose. The study results were presented at the… Read More
The US Food and Drug Administration (FDA) has granted full approval for Jemperli (dostarlimab-gxly) for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, as determined by a US FDA-approved test. The approval is for endometrial cancer that has progressed on or following a prior… Read More
An experimental vaccine against Marburg virus (MARV) was proved to be safe and induced an immune response in a small, first-in-human clinical trial. In areas of Africa where a vaccine for Marburg is most needed, a single-dose vaccine that could protect recipients over a long period of… Read More
Swedish start-up Atrogi has enrolled the first patient in its Phase Ia/b study of ATR-258, a novel b2adrenoceptor agonist for the treatment of type 2 diabetes and comorbidities. Conducted in Mannheim, Germany by Clinical Research Services (CRS), the trial is expected to be completed by April 2023… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Clinical trials have led our news section this week, with positive results… Read More
News round-up for 19-20 January by DDW Digital Content Editor Diana Spencer. Clinical trials have led our news section this week, with positive results announced from several Phase I and II studies. There was good news from Alto Neuroscience, everImmune, Avacta and Abionyx, though unfortunately things are not… Read More
The first patient has been treated in everImmune’s Phase I clinical trial evaluating its oncobiotic drug candidate Oncobax AK in lung and kidney cancer patients. The aim of the trial is to assess the toxicity and efficacy of Oncobax AK when administered alongside an immunotherapy treatment. … Read More
Cancer drug AVA6000 continues to show a very favourable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation Phase I clinical trial. Additionally, analysis of tumour biopsies obtained from six patients indicates that doxorubicin is being released within the tumour tissue, confirming the tumour… Read More
While scientists have struggled in the past to create an effective vaccine against HIV, a novel vaccine design strategy shows new promise, according to data from a first-in-human clinical trial. In a paper published in Science, the researchers reveal critical new insights… Read More
The first subject has been dosed in a Phase I biomarker study of apimostinel, a rapid-acting N-methyl-D-aspartate receptor (NMDAR) modulator for major depressive disorders (MDD). The injectable treatment was developed by clinical-stage biotechnology company Gate Neurosciences for acute depressive disorders… Read More
Beckley Psytech has completed its Phase I clinical study of BPL-003, a synthetic intranasal formulation of 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT). The drug is under development for Treatment Resistant Depression and Alcohol Use Disorder and was assessed in combination with psychological support in 44 psychedelic-naïve participants. Initial… Read More
DynamiCure has dosed the first patients in its Phase I clinical trial evaluating the first of the company’s two anti-CD93 monoclonal antibody candidates, DCBY02, in adults with a wide range of advanced cancers. CD93 is a novel target downstream of VEGF-A (vascular endothelial growth factor) that has been shown… Read More
